Objective To evaluate the cost-effectiveness of gadopentetate dimeglumine(Gd-DTPA)and gadobenate dimeglumine(Gd-BOPTA)magnetic resonance imaging(MRI)contrast agents for the early diagnosis of hepatocellular carcinoma(...Objective To evaluate the cost-effectiveness of gadopentetate dimeglumine(Gd-DTPA)and gadobenate dimeglumine(Gd-BOPTA)magnetic resonance imaging(MRI)contrast agents for the early diagnosis of hepatocellular carcinoma(HCC)from the perspective of China’s healthcare system.Methods A decision tree+partitioned survival model was constructed for early diagnosis of HCC based on literature data.Taking quality-adjusted life year(QALY)as the main health outcome measure for incremental cost-effectiveness ratio(ICER)analysis,the sensitivity analysis by Monte Carlo simulation was constructed to generate corresponding tornado diagram,incremental cost-effectiveness scatter plot,and cost-effectiveness acceptability curve.Results and Conclusion The basic analysis results showed that the ICER value of Gd-BOPTA diagnostic scheme compared with Gd-DTPA diagnostic scheme was 17302.46 yuan/QALY,which is less than 1 times of China’s gross domestic product(GDP)per capita.The sensitivity analysis results showed that the cost of delayed treatment and timely treatment had a significant impact on the results.When the willingness to pay(WTP)was 1 time of GDP per capita,the probability of cost-effectiveness advantage of Gd-BOPTA diagnostic scheme was 65.30%.When the WTP value is set at 1 times of GDP per capita,Gd-BOPTA MRI has cost-effectiveness advantages for the early diagnosis of HCC.展开更多
AIM To evaluate the diagnostic value of gadobenate dimeglumine(Gd-BOPTA)-enhanced hepatocyte-phase magnetic resonance imaging(MRI) in evaluating hepatic fibrosis and hepatitis.METHODS Hepatocyte-phase images of Gd-BOP...AIM To evaluate the diagnostic value of gadobenate dimeglumine(Gd-BOPTA)-enhanced hepatocyte-phase magnetic resonance imaging(MRI) in evaluating hepatic fibrosis and hepatitis.METHODS Hepatocyte-phase images of Gd-BOPTA-enhanced MRI were retrospectively evaluated in 76 patients with chronic liver disease. These patients were classified into five groups according to either the histopathological fibrosis stage(S0-S4) or the histopathological hepatitis grade(G0-G4). The relative enhancement ratio(RE) of the liver parenchyma in the T1-vibe sequence was calculated by measuring the signal intensity before(SI pre) and 90 min after(SI post) intravenous injection of Gd-BOPTA using the following formula: RE =(SI post-SI pre)/SI pre. One-way analysis of variance was used to compare the difference between the relative RE in the hepatocyte phase(REh) and the stage of hepatic fibrosis and the grade of hepatitis. Pearson's productmoment correlation analysis was used to evaluate the relationship between the REh and the levels of serologic liver functional parameters.RESULTS According to histopathological hepatic fibrosis stage, the 76 patients were classified into five groups: 16 in S0, 15 in S1, 21 in S2, 9 in S3, and 15 in S4 group. According to histopathological hepatitis grade, the 76 patients were also classified into five groups: 0 in G0, 44 in G1, 22 in G2, 8 in G3, and 2 in G3 group. With regard to the stage of hepatic fibrosis, REh showed significant differences between the S2 and S3 groups and between the S2 and S4 groups(P < 0.05), but no significant difference was observed between the other groups. With regard to the grade of hepatitis, REh showed significant differences between the G1 and G2 groups and between the G1 and G4 groups(P < 0.05), but no significant difference was observed between the other groups. Increased REh showed correlations with decreased serum levels of TB, ALT and AST(P < 0.05). CONCLUSION To some extent, measuring the REh using Gd-BOPTAenhanced MRI might be a noninvasive technique for assessing the stage of hepatic fibrosis. This method is able to differentiate no/mild hepatitis from advanced hepatitis. TB, ALT and AST levels can predict the degree of liver enhancement in the hepatocyte phase of Gd-BOPTA-enhanced MRI.展开更多
文摘Objective To evaluate the cost-effectiveness of gadopentetate dimeglumine(Gd-DTPA)and gadobenate dimeglumine(Gd-BOPTA)magnetic resonance imaging(MRI)contrast agents for the early diagnosis of hepatocellular carcinoma(HCC)from the perspective of China’s healthcare system.Methods A decision tree+partitioned survival model was constructed for early diagnosis of HCC based on literature data.Taking quality-adjusted life year(QALY)as the main health outcome measure for incremental cost-effectiveness ratio(ICER)analysis,the sensitivity analysis by Monte Carlo simulation was constructed to generate corresponding tornado diagram,incremental cost-effectiveness scatter plot,and cost-effectiveness acceptability curve.Results and Conclusion The basic analysis results showed that the ICER value of Gd-BOPTA diagnostic scheme compared with Gd-DTPA diagnostic scheme was 17302.46 yuan/QALY,which is less than 1 times of China’s gross domestic product(GDP)per capita.The sensitivity analysis results showed that the cost of delayed treatment and timely treatment had a significant impact on the results.When the willingness to pay(WTP)was 1 time of GDP per capita,the probability of cost-effectiveness advantage of Gd-BOPTA diagnostic scheme was 65.30%.When the WTP value is set at 1 times of GDP per capita,Gd-BOPTA MRI has cost-effectiveness advantages for the early diagnosis of HCC.
基金Supported by National Natural Science Foundation of China,Nos.81571784 and 81601471Scientific and Technological Support Project for Social Development of Hunan Province,No.2015SF2020-4Project of Development and Reform Commission of Hunan Province,No.Xiang Cai Enterprise Means[2015]83
文摘AIM To evaluate the diagnostic value of gadobenate dimeglumine(Gd-BOPTA)-enhanced hepatocyte-phase magnetic resonance imaging(MRI) in evaluating hepatic fibrosis and hepatitis.METHODS Hepatocyte-phase images of Gd-BOPTA-enhanced MRI were retrospectively evaluated in 76 patients with chronic liver disease. These patients were classified into five groups according to either the histopathological fibrosis stage(S0-S4) or the histopathological hepatitis grade(G0-G4). The relative enhancement ratio(RE) of the liver parenchyma in the T1-vibe sequence was calculated by measuring the signal intensity before(SI pre) and 90 min after(SI post) intravenous injection of Gd-BOPTA using the following formula: RE =(SI post-SI pre)/SI pre. One-way analysis of variance was used to compare the difference between the relative RE in the hepatocyte phase(REh) and the stage of hepatic fibrosis and the grade of hepatitis. Pearson's productmoment correlation analysis was used to evaluate the relationship between the REh and the levels of serologic liver functional parameters.RESULTS According to histopathological hepatic fibrosis stage, the 76 patients were classified into five groups: 16 in S0, 15 in S1, 21 in S2, 9 in S3, and 15 in S4 group. According to histopathological hepatitis grade, the 76 patients were also classified into five groups: 0 in G0, 44 in G1, 22 in G2, 8 in G3, and 2 in G3 group. With regard to the stage of hepatic fibrosis, REh showed significant differences between the S2 and S3 groups and between the S2 and S4 groups(P < 0.05), but no significant difference was observed between the other groups. With regard to the grade of hepatitis, REh showed significant differences between the G1 and G2 groups and between the G1 and G4 groups(P < 0.05), but no significant difference was observed between the other groups. Increased REh showed correlations with decreased serum levels of TB, ALT and AST(P < 0.05). CONCLUSION To some extent, measuring the REh using Gd-BOPTAenhanced MRI might be a noninvasive technique for assessing the stage of hepatic fibrosis. This method is able to differentiate no/mild hepatitis from advanced hepatitis. TB, ALT and AST levels can predict the degree of liver enhancement in the hepatocyte phase of Gd-BOPTA-enhanced MRI.
